Dried blood spots (DBS) are widely used in newborn screening, but most analytical workflows examine only one molecular class at a time, limiting the biochemical information obtained from each small sample. Analyzing both metabolites and lipids from a single dried blood sample could provide a broader biochemical profile and help researchers investigate changes associated with health and disease.
Timothy Garrett and Esabella Powers, both from the Department of Chemistry at the University of Florida, USA, have developed a protocol that extracts both molecular classes for analysis by liquid chromatography-high-resolution tandem mass spectrometry (LC-HRMS/MS).
Here, Garrett and Powers discuss the practical challenges of analyzing both molecular classes from a single 10 µL sample, the factors that affect data interpretation, and the further development and clinical validation needed to assess the approach’s potential for broader newborn screening and diagnostic use.
What inspired this research?
This research was inspired by newborn screening, which uses DBS to detect a range of conditions, including inborn errors of metabolism identified through specific metabolites. DBS sampling is also used more broadly because it offers analyte stability, minimally invasive collection, and straightforward storage and transport.
Researchers have analyzed metabolites, lipids, proteins, RNA, and DNA from DBS, but usually one molecular class at a time. We therefore developed a method to analyze both metabolites and lipids from a single sample. Because DBS specimens are small and often limited, our aim was to obtain more information from the available blood and potentially expand the analytical scope of newborn screening.
How was LC-MS/MS used, and what information did it provide?
Following extraction, the lipids and metabolites were analyzed using LC–HRMS/MS. Metabolite data were processed in MZmine, with compounds identified through MS/MS spectral matching and an in-house LC-MS library based on mass-to-charge ratio and retention time.
Lipids were annotated using LipidMatch, which combines data-dependent MS/MS and full-scan mass spectrometry data to assign and score identifications. Together, the identities and relative abundances of these molecules provide a snapshot of biochemical activity that may offer insight into health and disease.
What challenges are associated with developing a multi-omics approach to dried blood spot analysis, and how did you overcome them?
Developing a multi-omics method for DBS analysis presented several challenges. Lipids and polar metabolites have different chemical properties, making it difficult to extract both efficiently from the same sample. We addressed this using a biphasic extraction modeled on the Folch method, which partitions lipids into the organic phase and metabolites into the aqueous phase. This allows both molecular classes to be analyzed from a single DBS.
The small volume of blood in each spot also produced low analyte signals. We therefore used a lower reconstitution volume than in our standard plasma and serum workflows, concentrating the analytes and improving signal intensity. To minimize polyethylene glycol contamination, we used glass pipettes and tubes throughout the procedure.
How did you ensure the reliability and reproducibility of data generated from dried blood spot samples?
To assess reliability and reproducibility, we performed multiple DBS extractions from the same donors on different days. Each lipid and metabolite extract was analyzed using the same workflow, and the results were compared across extractions.
Could the LC-MS/MS findings be integrated with the other omics data?
Because the metabolomic and lipidomic datasets are generated by LC–HRMS/MS from the same DBS, they can be integrated directly. We have not yet combined these results with other omics data because no additional analyses have been performed on the samples. However, we are working to incorporate proteomics into the same workflow, which would enable broader multi-omics integration.
What should laboratory professionals consider when interpreting or applying these findings?
Laboratory professionals should consider specimen type when interpreting these findings because metabolite and lipid concentrations can differ between whole blood collected as DBS and plasma or serum. Values measured in DBS may therefore not be directly comparable with reference values established using other matrices.
Drying and storage can also alter the molecular profile through oxidation, reduction, or other chemical changes. Hematocrit and spot volume are additional sources of variability because hematocrit affects how blood spreads across the card and how much is present in each punch.
To reduce these effects, we used volumetric DBS devices that collect a fixed 10 µL volume of blood. Laboratories should account for these pre-analytical factors when applying the method, particularly if they use conventional non-volumetric DBS cards.
What impact could combining DBS with multiomics have for diagnostics and healthcare more broadly?
Combining DBS sampling with multi-omics analysis could support the detection of several metabolic and lipid-related disorders from a single, low-volume specimen. Because DBS are minimally invasive and straightforward to collect, store, and transport, the approach may also expand access to testing in remote or resource-limited settings.
DBS are already routinely collected for newborn screening, creating a potential route for broader multi-omics analysis. However, further method development and clinical validation using samples from affected patients are needed before the approach can be applied diagnostically.
What are your future plans?
We are continuing to optimize the method by evaluating alternative extraction procedures and adding proteomic analysis. Greater mass spectrometry sensitivity could improve the detection of low-abundance compounds, while faster workflows could increase sample throughput. Expanded spectral libraries and improved use of fragmentation data would also support more confident metabolite identification.
Further optimization of DBS extraction may broaden molecular coverage, and targeted assays could be developed for metabolites of particular clinical interest. Incorporating proteomics and other omics layers could ultimately provide a more comprehensive profile from a single blood spot.
